XCSport体育

<form id='XYk0w'></form>

<bdo id='NAxn4'><sup id='H3efh'><div id='SSiTN'><bdo id='FrI2f'></bdo></div></sup></bdo>

Be the most trusted biotech company

2024-07-06

Henlius Welcomed SAB Member Alberto Mantovani to its Shanghai Innovation Centre
2024-07-03

Henlius Forecasts Profit in 2023 H1: Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle
2024-06-28

Henlius Holds its 1st Overseas Scientific Advisory Board Meeting of 2023
2024-06-26

Henlius Immune Checkpoints Inhibitor Anti-CTLA-4 mAb Received IND Approval for the Treatment of HCC
2024-06-15

First Patient Dosed of Phase 2 Clinical Trial of Serplulimab in Combination with Innovative Anti-LAG-3 mAb for the Treatment of Metastatic Colorectal Cancer Patients
2024-06-12

Henlius Shines for Five Consecutive Years at BIO International Convention
2024-06-06

Results From the Phase 2 Clinical Trial of HLX07 for the Treatment of ESCC Released at 2023 ASCO
2024-06-06

Results From the Phase 2 Clinical Trial of Henlius BRAFV600E Inhibitor HLX208 for the Treatment of LCH and/or ECD Released at 2023 ASCO Annual Meeting
2024-05-26

2023 ASCO Annual Meeting Released Clinical Data of Two Henlius Trials

1
2
3
4
5
6
7
8